Beone Medicines LTD. 8-K Filing

Ticker: BEIGF · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1651308

Beone Medicines LTD. 8-K Filing Summary
FieldDetail
CompanyBeone Medicines LTD. (BEIGF)
Form Type8-K
Filed DateDec 19, 2025
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Beone Medicines LTD. (ticker: BEIGF) to the SEC on Dec 19, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.0001 (resenting 13 Ordinary Shares, par value $0.0001 per share ONC The NASDAQ Global Selec).

How long is this filing?

Beone Medicines LTD.'s 8-K filing is 2 pages with approximately 606 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2025-12-19 06:01:09

Key Financial Figures

Filing Documents

02. Termination of a Material Definitive Agreement

Item 1.02. Termination of a Material Definitive Agreement. As previously disclosed in its Current Report on Form 8-K filed on November 19, 2025, BeOne Medicines Ltd. (the "Company") entered into the Facilities Agreement (the "Facilities Agreement"), by and among (i) certain subsidiaries of the Company listed in the Facilities Agreement, as guarantors, (ii) The Hongkong and Shanghai Banking Corporation Limited, as global coordinator, original mandated lead arranger and bookrunner, agent and security agent, and (iii) certain financial institutions listed in the Facilities Agreement, as lenders. On December 16, 2025, the Company utilized a portion of the proceeds from borrowings under the Facilities Agreement to repay in full all outstanding amounts owed under the Company's Facility Agreement, dated as of December 9, 2024, by and between the Company and China Merchants Bank Co., Ltd. (the "CMB Credit Facility"), and terminated all commitments by the lender to extend further credit under the CMB Credit Facility and all guarantees and security interests granted by the Company to the lender under the CMB Credit Facility. No termination penalties were incurred by the Company in connection with the termination of the CMB Credit Facility. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEONE MEDICINES LTD. Date: December 19, 2025 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing